A086040 Stock Overview
Engages in the safety evaluation of synthetic medicines, biomedicines, cell therapy products, gene therapy products, health functional foods, chemicals, and pesticides in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Biotoxtech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,265.00 |
| 52 Week High | ₩7,430.00 |
| 52 Week Low | ₩2,905.00 |
| Beta | 0.34 |
| 1 Month Change | 7.23% |
| 3 Month Change | -24.16% |
| 1 Year Change | -45.67% |
| 3 Year Change | -59.34% |
| 5 Year Change | -48.01% |
| Change since IPO | -57.71% |
Recent News & Updates
Recent updates
Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their Feet
Oct 21
Is Biotoxtech (KOSDAQ:086040) A Risky Investment?
May 06Estimating The Fair Value Of Biotoxtech Co., Ltd. (KOSDAQ:086040)
Mar 28Did Biotoxtech's (KOSDAQ:086040) Share Price Deserve to Gain 91%?
Feb 20Are Robust Financials Driving The Recent Rally In Biotoxtech Co., Ltd.'s (KOSDAQ:086040) Stock?
Jan 24
We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory Earnings
Dec 27Is Biotoxtech (KOSDAQ:086040) Using Too Much Debt?
Nov 30Shareholder Returns
| A086040 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | -4.5% | -3.7% | -0.9% |
| 1Y | -45.7% | 32.0% | -9.0% |
Return vs Industry: A086040 underperformed the KR Life Sciences industry which returned 33.7% over the past year.
Return vs Market: A086040 underperformed the KR Market which returned -9% over the past year.
Price Volatility
| A086040 volatility | |
|---|---|
| A086040 Average Weekly Movement | 7.0% |
| Life Sciences Industry Average Movement | 9.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A086040 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A086040's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 198 | Jong-Koo Kang | www.biotoxtech.com |
Biotoxtech Co., Ltd. engages in the safety evaluation of synthetic medicines, biomedicines, cell therapy products, gene therapy products, health functional foods, chemicals, and pesticides in South Korea. It is involved in testing and substance screening, clinical pathology and histopathology work, and consulting and government affairs related to non-clinical trials, as well as new drug development. The company’s safety evaluation research field includes general toxicity test, carcinogenicity studies, local toxicity studies, reproductive and developmental studies, genotoxicity test, immunotoxicity test, safety pharmacology test, aquatic ecotoxicology test, histopathology/clinical pathology, and animal testing method.
Biotoxtech Co., Ltd. Fundamentals Summary
| A086040 fundamental statistics | |
|---|---|
| Market cap | ₩51.33b |
| Earnings (TTM) | -₩4.41b |
| Revenue (TTM) | ₩38.44b |
1.3x
P/S Ratio-11.6x
P/E RatioIs A086040 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A086040 income statement (TTM) | |
|---|---|
| Revenue | ₩38.44b |
| Cost of Revenue | ₩37.02b |
| Gross Profit | ₩1.43b |
| Other Expenses | ₩5.84b |
| Earnings | -₩4.41b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -280.52 |
| Gross Margin | 3.71% |
| Net Profit Margin | -11.47% |
| Debt/Equity Ratio | 167.7% |
How did A086040 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 05:19 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biotoxtech Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Young Ok Kim | DAOL Investment & Securities Co., Ltd. |
| Seung-Ho Lee | iM Securities |